MarketLens
Sign Up

Is Harmony Biosciences' Growth Story Still Compelling in 2026

8 months ago
SHARE THIS ON:

Is Harmony Biosciences' Growth Story Still Compelling in 2026

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•4 days ago

Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It

Harmony Biosciences was rated Buy with a $43 12-month price target, citing strong cash generation and WAKIX growth. The call flags limited downside if patents hold through 2030, but pending AET patent...
Stock News•1 week ago

HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?

Harmony Biosciences rose 27.6% over six months as Wakix sales surged and pipeline advanced, with new formulations and clinical milestones offering further growth opportunities.
Stock News•1 week ago

Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit

Harmony Biosciences shares fell Monday after the company announced CEO Jeffrey Dayno will exit at the end of the year. The leadership transition introduces uncertainty as the biotech searches for a su...

Breaking News

View All →

Top Headlines

View More →
Stock News•3 hours ago

Elon Musk Just Gave Fantastic News for Nvidia Investors

Stock News•5 hours ago

Peter Thiel says Apple has done 'nothing new' after Steve Jobs

Stock News•8 hours ago

Meet Wall Street's Newest Major Stock Split: It Has Soared 1,730% Since Its 2012 IPO, and There Is Plenty of Upside Left

Stock News•8 hours ago

PC Sales Just Crashed 21% as AI Eats the World's Memory Chips

Stock News•10 hours ago

CrowdStrike's CEO Says a Wave of Cyber Attacks Are Coming